Junshi Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Junshi Biosciences's estimated annual revenue is currently $11.3M per year.
- Junshi Biosciences's estimated revenue per employee is $155,000
Employee Data
- Junshi Biosciences has 73 Employees.
- Junshi Biosciences grew their employee count by -13% last year.
Junshi Biosciences's People
| Name | Title | Email/Phone |
|---|
Junshi Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Junshi Biosciences?
Junshi Biosciences is an innovation-driven biopharmaceutical company which is dedicated to the discovery and development of innovative drugs and their clinical research and commercialization on a global scale. Our mission is to provide patients with treatment options that work better and cost less.
keywords:N/A
N/A
Total Funding
73
Number of Employees
$11.3M
Revenue (est)
-13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Junshi Biosciences News
Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United...
Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for Anti-CD112R Monoclonal Antibody for Treatment of...
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the...
Other Companies in Shanghai
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $19.8M | 79 | -10% | N/A |
#2 | $24.7M | 81 | 4% | N/A |
#3 | $12.7M | 82 | -2% | N/A |
#4 | $12M | 83 | 6% | N/A |
#5 | $12.2M | 84 | -1% | N/A |